In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Just a couple of months after Novo Nordisk shook up the big diabetes market with the arrival of its GLP-1 drug Ozempic (semaglutide) in the US, the big Danish company has begun rolling out the first in a long lineup of Phase III studies for its next-gen oral version of the drug. And the debut of the Phase III data started out on a positive note.
Researchers for Novo say that the first of 10 Phase III studies that read out this year came with statistically significant results on all three doses tested. And if they can stay on track, they plan to field the first ever oral GLP-1 to regulators in 2019, vowing to command an even bigger share of the mega blockbuster market after overcoming some huge hurdles in developing an oral peptide therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.